» Articles » PMID: 28808361

Interleukin-6: An Early Predictive Marker for Severity of Acute Pancreatitis

Overview
Specialty Critical Care
Date 2017 Aug 16
PMID 28808361
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Interleukin (IL)-6, IL-8, IL-10, and C-reactive protein (CRP) have been evaluated for predicting outcomes of acute pancreatitis. However, there is considerable variation in their performance among different studies. We evaluate their accuracy in predicting progression to severe pancreatitis.

Materials And Methods: Serum IL-6, IL-8, IL-10, and CRP levels were measured within 24 h of admission in forty patients of clinically predicted severe acute pancreatitis (SAP). Persistent organ failure (>48 h) defined SAP. The performance of inflammatory markers was evaluated in predicting the progression of pancreatitis.

Results: IL-6 ≥28.90 pg/mL had a sensitivity of 62.86%, specificity of 80%, positive predictive value (PPV) of 95.65%, LR+ of 3.1429, LR- of 0.4643, and diagnostic odds ratio (DOR) of 6.7692; IL-8 ≥88.70 pg/mL had a sensitivity of 60%, specificity of 80%, PPV of 95.45%, LR+ of 3.000, LR- of 0.5000, and DOR of 6.000; IL-10 ≤5.70 pg/mL had DOR of 0.2647, sensitivity of 51.43%, specificity of 20%, PPV of 81.82%, LR+ of 0.6429, and LR- of 2.4286. CRP ≥110.00 mg/L had DOR of 2.3636, sensitivity of 37.14%, specificity of 80%, PPV of 92.86%, LR+ of 1.8571, and LR of 0.7857.

Conclusions: IL-6 ≥28.90 pg/mL, measured within 48 h of onset is the best among the tested biomarkers in this study for predicting the progression to severe pancreatitis.

Citing Articles

Overview of the cellular and immune mechanisms involved in acute pancreatitis: In search of new prognosis biomarkers.

Mititelu A, Grama A, Colceriu M, Pop T, Pop T Expert Rev Mol Med. 2025; 27:e9.

PMID: 39757373 PMC: 11879381. DOI: 10.1017/erm.2024.40.


Effect and safety of sivelestat on acute severe pancreatitis with systemic inflammatory response syndrome: a retrospective study.

Xie J, Lei R, Pei H, Gu Y, Zhang L, Liu J Sci Rep. 2025; 15(1):150.

PMID: 39747371 PMC: 11695592. DOI: 10.1038/s41598-024-84600-z.


Role of Interleukin 6 in Acute Pancreatitis: A Possible Marker for Disease Prognosis.

Mititelu A, Grama A, Colceriu M, Benta G, Popoviciu M, Pop T Int J Mol Sci. 2024; 25(15).

PMID: 39125854 PMC: 11311934. DOI: 10.3390/ijms25158283.


Acute pancreatitis: pathogenesis and emerging therapies.

Zaman S, Gorelick F J Pancreatol. 2024; 7(1):10-20.

PMID: 38524855 PMC: 10959536. DOI: 10.1097/JP9.0000000000000168.


Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP) protocol and statistical analysis plan: a prospective, multicentre, double-blind, randomized, placebo controlled clinical trial.

Vine J, Berlin N, Moskowitz A, Berg K, Liu X, Balaji L Contemp Clin Trials. 2024; 139:107486.

PMID: 38431131 PMC: 11131038. DOI: 10.1016/j.cct.2024.107486.


References
1.
Heath D, Cruickshank A, Gudgeon M, Jehanli A, Shenkin A, Imrie C . Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. Gut. 1993; 34(1):41-5. PMC: 1374098. DOI: 10.1136/gut.34.1.41. View

2.
Ranson J, Rifkind K, Turner J . Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gynecol Obstet. 1976; 143(2):209-19. View

3.
Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V . Early antibiotic treatment in acute necrotising pancreatitis. Lancet. 1995; 346(8976):663-7. DOI: 10.1016/s0140-6736(95)92280-6. View

4.
Blamey S, Imrie C, ONeill J, Gilmour W, Carter D . Prognostic factors in acute pancreatitis. Gut. 1984; 25(12):1340-6. PMC: 1420197. DOI: 10.1136/gut.25.12.1340. View

5.
Baggiolini M, Walz A, Kunkel S . Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989; 84(4):1045-9. PMC: 329758. DOI: 10.1172/JCI114265. View